positive
Recently
Lupin reports 73% YoY surge in Q2 PAT on higher global sales
Lupin’s Q2 FY26 PAT rose 73% YoY to ₹1,485 crore with revenue up 24%, driven by strong US generics and higher margins boosting investor sentiment.
Lupin Ltd announced a 73% year-on-year increase in consolidated Q2 FY26 profit after tax to ₹1,485 crore, supported by revenue growth of 24% to ₹6,831 crore. The pharmaceutical major cited robust performance in the US generics market, margin improvement, and favorable currency trends. Management highlighted continued progress on complex generics and specialty drug portfolios.
The results exceeded analyst expectations, boosting optimism for FY26. Shares of Lupin traded higher post-announcement, reflecting confidence in its operational and geographic expansion strategy.